CEO of Amazon’s One Medical steps down

The CEO of Amazon’s One Medical has stepped down after less than two years in the role, employees were informed in an internal email Tuesday.

Trent Green had been CEO of One Medical since September 2023, taking over shortly after Amazon purchased the primary care company for $3.9 billion

In an announcement, Green stated that he will be taking over the CEO role at National Research Corporation, a data analytics company. He will begin his new position June 1.

His replacement at One Medical has not yet been named, and Green’s final day in his current role was not disclosed.

Since the Amazon takeover, One Medical has expanded its telehealth operations, partnering with major health systems, including Duke University Health, Mass General Brigham and Emory Healthcare. 

However, the company has been embroiled in a serious scandal in California after a provider allegedly told an emergency patient who was coughing up blood to buy an inhaler. The patient died in an Oakland emergency room hours later, leading his family to file a lawsuit accusing One Medical of lacking “adequately trained and qualified staff.”

The outcome of that lawsuit is still pending.

One Medical, founded in 2007, provides both virtual and in-person primary and urgent care services to patients. Amazon purchased the company in February 2023.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.